Expanded Access To MLN8237, For An Individual Patient With Adenocarcinoma Of The Prostate (CTMS# 16-0122)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Alisertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Expanded access; Therapeutic Use
- 03 Jan 2017 New trial record